Registro de fonte primária
O diagnóstico complementar VENTANA MMR RxDx Panel recebeu aprovação IVDR na UE para uso expandido em cinco tipos de câncer e seis indicações terapêuticas. A rotulagem agora abrange KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), IMFINZI+LYNPARZA e JEMPERLI (dostarlimab) para tumores dMMR ou pMMR em cânceres colorretais, endometriais, gástricos, de intestino delgado e biliares.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies USA - English USA - English News provided by Roche Jun 11, 2026, 01:00 ET Share this article Share to X Share this article Share to X Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option to determine mismatch repair (MMR) status This IVDR approval expands the companion diagnostic's label to include five cancer types